ANI Pharmaceuticals is a pharmaceutical company focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The company's products include, among others: Arimidex, which is used for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer; Erythromycin Ethylsuccinate, which is used to treat infections caused by susceptible strains of designated organisms for selected diseases; Diphenoxylate Hydrochloride and Atropine Sulfate, which is used as an adjunctive therapy in the management of diarrhea; and Etodolac, which is used to treat mild to moderate pain caused by osteoarthritis and rheumatoid arthritis.

Appian provides low-code automation platform that accelerates the creation of business applications, enabling its customers to automate their business. The company's platform automates the creation of forms, data flows, records, reports and other software elements that would otherwise need to be manually coded. The company'snSelf-Assembling Interface Layer technology ensures that applications developed on its platform can be deployed across a range of mobile and desktop devices, including desktop web browsers, tablets and mobile phones. The company's platform can be deployed in the cloud or on-premises, with organizations able to access the same functionality and data sources in various cases.

Camden National is a bank holding company. The primary business of the company and its subsidiary, Camden National Bank (the Bank), is to accept deposits from, and to extend loans to, consumer, institutional, municipal, non-profit and commercial customers. The Bank, through Camden National Wealth Management, provides a range of fiduciary and asset management services to both individual and institutional clients, and through Camden Financial Consultants, provides brokerage and insurance and its financial offerings include college, retirement, and estate planning, mutual funds, strategic asset management accounts, and variable and fixed annuities.

Eastman Kodak is a commercial printing and imaging company with proprietary technologies in materials science, digital imaging science and software, and deposition processes. The company provides directly and through partnerships with other companies hardware, software, consumables and services to customers in graphic arts, commercial print, publishing, electronic displays, entertainment and commercial films, and consumer products markets. The company also provides brand licensing and intellectual property opportunities, provides products and services for motion pictures and other commercial films, and sells ink to its existing installed consumer inkjet printer base.

GMS is a holding company. Through its subsidiaries, the company is engaged as a building products including wallboard, suspended ceilings systems, or ceilings, steel framing and other complementary building products. The company's product offering are: wallboard for interior and exterior walls and ceilings in residential and commercial structures; ceilings, which consists of suspended mineral fiber, soft fiber and metal ceiling systems; Steel Framing, which consists of steel track, studs and the various other steel products; and Other Products, which includes complementary products such as insulation, lumber, ready-mix-joint compound and various other interior construction products and ancillary products.

Kezar Life Sciences is a clinical-stage biotechnology company, discovering and developing small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The company's product candidate, KZR-616, an immunoproteasome inhibitor, is enrolling a clinical trial across different separate autoimmune indications: lupus nephritis; autoimmune hemolytic anemia, and immune thrombocytopenia; and dermatomyositis, and polymyositis. The company is also utilizing its protein secretion pathway research platform to discover and develop small molecule therapies targeting oncology indications.

Net 1 UEPS Technologies provides financial technology, products and services. The company has developed and owns most of its payment technologies, and where possible, utilizes this technology to provide financial and services to its customers by including them into the formal financial system. The company's primary payment technology is called the Universal Electronic Payment System (UEPS), and its EMV interoperable derivative, UEPS/EMV, utilizes a form of distributed ledger technology, providing decentralized and biometrically secure smart cards that operate in real-time but both off-line and on-line. The company's financial inclusion products and services are delivered through its UEPS-based core banking system.

SecureWorks is a holding company. Through its subsidiaries, the company provides information security solutions focused on protecting its customers from cyber attacks. The company's integrated suite of solutions include: managed security, through which it provides its customers global visibility and insight into malicious activity enabling them to detect and remediate threats; and security and risk consulting, through which it advises its customers on a variety of security and risk-related matters. The company's proprietary Counter Threat Platform collects, aggregates, correlates and analyzes daily events from its customer base and uses algorithms to detect malicious activity and deliver security countermeasures.